

#### Q&A

- Please submit all questions concerning webinar content through the Q&A panel.
- Reminder:
- If you have participants watching this webinar at your site, please collect their names and emails.
  - We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar.

N4ACCR



# Agenda • Overview • Collaborative Stage • Treatment



# Key Facts Cervix New cases: 12,170 Deaths: 4,220 Cervical cancer is decreasing in the U.S. Cervical cancer is increasing in developing countries

#### **Key Facts**

- Endometrial carcinoma estimated 2012 cases in the U.S.
  - New cases: 47,130
  - Deaths: 8,010

NAACC

#### **Key Facts**

#### 5 year Relative Survival Rates (%) by Stage at Diagnosis, 2001-2007

	Local	Regional	Distant
Uterine Cervix	91	57	19
Uterine Corpus	96	67	16

Source: Howlader N, Krapcho M, Neyman N, et al. (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD, www.seer.cancer.gov/csr/1975\_2008/, 2011.

NAACCR<sup>2</sup>

#### **Risk Factors**

- Cervical carcinoma
  - HPV
  - Smoking
  - Immunosuppression
  - Chlamydia infection
  - Diet
  - Birth control pills

#### **Human Papilloma Virus (HPV) Infection**

- Epidemiologic studies convincingly demonstrate that the major risk factor for development of preinvasive or invasive carcinoma of the cervix is HPV infection
  - About two-thirds of all cervical cancers are caused by HPV 16 and 18
  - Infection with HPV is common
  - Pap tests look for changes in cervical cell caused by HPV infection

NAACCR

#### **Risk Factors**


- · Endometrial carcinoma
  - Post menopausal estrogen therapy (unopposed)
  - Obesity
  - High-fat diet
  - Early menarche and late menopause


NAACCR<sup>2</sup>


#### **Symptoms**


- Cervix
  - Often asymptomatic
  - Screening
- HPV Vaccine
- Endometrium
  - Abnormal vaginal bleeding (most often in postmenopausal period)


NAACCR<sup>2</sup>











#### Terminology

- -plasia: Growth or development
  - Neoplasia: New growth or development
  - Hyperplasia: Rapid growth or development
  - Dysplasia: Abnormal growth of tissues, organs, or cells
  - Metaplasia: Replacement of one differentiated cell type with another mature differentiated cell type

NAACCR<sup>\*</sup>

#### **Cancer Histology of the Cervix** Cervical Intraepithelial Neoplasia (CIN) I, II, III Carcinoma In Situ of the Cervix - Bowen's disease - Stage 0 Surface CIN grade IIIConfined to epithelium Basement Intraepidermal membrane Intraepithelial Cancerous Stroma or Noninfiltrating Noninvasive - No stromal involvement N4ACCR<sup>2</sup>

### Carcinoma In Situ of the Cervix, CIN, and the Bethesda System

- Pre-invasive cervical neoplasia
  - Diagnostic terminology has changed over time
    - Four tiered system of dysplasia and carcinoma in situ
    - Three tiered system of CIN
    - Two tiered Bethesda System with high and low grade squamous intraepithelial lesions
  - In the past registries collected carcinoma in situ of the cervix, but differed on which terms were synonymous.

NAACCR


### Carcinoma In Situ of the Cervix, CIN, and the Bethesda System


- In 1993 a NAACCR multidisciplinary group recommended that until
  - There is a strong local interest
  - Sufficient resources are available to collect all high grade squamous intraepithelial lesions

That population based registries discontinue collection

- NAACCR and NPCR adopted this recommendation at that time.
- SEER and CoC adopted it effective for 1/1/1996.

NAACCI





# Histology Adenocarcinoma of the endometrium • Type 1 - Endometrioid adenocarcinoma 75-80% • Type 2 - Papillary serous carcinoma 10% - Clear cell carcinoma 4% - Mucinous carcinoma 1% - Mixed 10%

Required Histology	Combined Histology	Combination Term	Code
Gyn malignancies with two or more of the histologies in column 2	Clear Cell	Mixed cell	8323/3
	Endometrioid	adenocarcinoma	
	Mucinous		
	Papillary		
	Serous		
	Squamous		
	Transitional		

#### **Example**

- A single tumor of the endometrium:
  - Endometrioid with squamous and focal clear cell differentiation.
- Rule H16 refers us to Table 2
  - Mixed cell adenocarcinoma 8323/3


NAACCR)


#### Histology


- Carcinosarcoma (CS Schema Carcinoma and Carcinosarcoma)
  - Mixed Mullerian
- Leiomyosarcoma
  - Rhabdomysarcoma
- Endometrial stromal sarcoma
- Adenosarcoma

#### **FIGO Grade**


- Is not the same as FIGO Stage
  - Grade 1: <5% of the tumor is solid
  - Grade 2: 5-50% of the tumor is solid
  - Grade 3: >50% of the tumor is solid
- Do not convert FIGO Grade to Histologic Grade/Differentiation














#### Uterus Schemas CS v02.04

- Cervix Uteri (C53.0 C53.9)
- Carcinoma and Carcinosarcoma of Corpus Uteri (C54.0-C54.9); Uterus NOS (C55.9)
- Adenosarcoma of the Corpus Uteri (C540-C54.9); Uterus NOS (C55.9)
- Sarcoma (Leiomyosarcoma and Endometrial Stromal Sarcoma) of the Corpus Uteri (C54.0-C54.9); Uterus NOS (C55.9)

NAACCR<sup>2</sup>



#### **CS Extension: Cervix Uteri**

- Record code with extension detail when both extension detail and FIGO stage are stated
- FIGO stage IIIB based on tumor extension AND regional node involvement; FIGO stage IV based on tumor extension AND metastasis
  - Code FIGO stage IIIB or IV in CS extension if based on tumor extension
- Macroscopically visible lesions T1b FIGO stage IB even with superficial invasion
- Code involvement of anterior or posterior septum as involvement of the vaginal wall

NAACCR

#### **CS Extension: Cervix Uteri**

- Codes 000-010: In situ; CIN III
- Codes 110-390: Confined to uterus
- Codes 400-550: Invasion beyond uterus but not to pelvic wall or to lower third of vagina
- Codes 605-690: Extension to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or nonfunctioning kidney
- Codes 700-860: Invades mucosa of bladder or rectum, and/or extends beyond true pelvis

NAACCR<sup>2</sup>

#### **Pop Quiz**

 Villoglandular adenocarcinoma of endocervix involving entire endocervix invasive to a depth of 3 mm. 5 cm tumor grossly extends into corpus uteri involving posterior endometrium and also has myometrial invasion. Large right ovarian tumor with metastatic endocervical adenocarcinoma with surface involvement.
 FIGO stage IB2.

#### **Pop Quiz**

- What is the code for CS Extension?
  - 110: Minimal microscopic stromal invasion < or = to 3 mm in depth and < than or = to 7 mm in horizontal spread
  - 220: FIGO Stage IB2
  - 350: Corpus uteri NOS with no other information on extension
  - 360: 350 + 110
  - 380: 350 + (200 or 250)
  - -390: 350 + (300 or 310)

NAACCR

#### **CS Lymph Nodes: Cervix Uteri**

- Code involvement of regional nodes
- FIGO stage IIIB
  - Based on tumor extension AND regional node involvement
    - Code statement of FIGO stage IIIB based on lymph node involvement in CS Lymph Nodes
    - Code statement of FIGO stage IIIB with no other information on tumor extension or regional node involvement in CS Lymph Nodes

NAACCR<sup>2</sup>

#### CS Mets at DX: Cervix Uteri

- Record code with metastasis detail when both metastasis detail and FIGO stage are stated
- FIGO stage IV
  - Based on tumor extension AND metastasis
    - Code statement of FIGO stage IV based on metastasis in CS Mets at DX
    - Code statement of FIGO stage IV with no other information on tumor extension or metastasis in CS Mets at DX

#### **FIGO Stage**

- Federation of Gynecology and Obstetrics (FIGO) stage
  - Collected for all gynecologic sites
  - Adapted in AJCC staging
  - Definitions vary from primary to primary
  - In situ stage no longer included for vulva, vagina, cervix, corpus (all histologies), ovary, fallopian tube, placenta, or peritoneum

NAACCI

#### SSF1: Cervix Uteri

- FIGO stage
  - Code as documented in medical record
    - Do not try to code from T, N, M values
  - Assign code 987 for carcinoma in situ or CIN III
    - CS Extension = 000 or 010
  - Assign code 999 if FIGO stage is unknown or not documented

NAACCR<sup>\*</sup>

#### **Status & Assessment of Lymph Nodes**

- Involvement of regional and distant nodes is prognostic factor for gynecologic sites
- Lymph node status
  - Positive
  - Negative
  - Not assessed
- Lymph node assessment
   Clinical
  - Radiography, imaging
  - Incisional biopsy, fine needle aspiration
  - Lymphadenectomy

# Status & Assessment of Lymph Nodes Cervix Uteri

- SSF2: Pelvic Nodal Status
- SSF3: Assessment Method Pelvic Nodal Status
- SSF4: Para-aortic Nodal Status
- SSF5: Assessment Method Para-aortic Nodal Status
- SSF6: Mediastinal Nodal Status
- SSF7: Assessment Method Mediastinal Nodal Status
- SSF8: Scalene Nodal Status
- SSF9: Assessment Method Scalene Nodal Status

NAACCR

# CARCINOMA & CARCINOSARCOMA OF CORPUS UTERI

# CS Extension: Carcinoma & Carcinosarcoma of Corpus Uteri

- Record code with extension detail when both extension detail and FIGO stage are stated
- FIGO stage
  - IIIA & IIIB are extension
  - IIIC is regional node involvement
  - IVA is extension
  - IVB is metastasis
- Positive cytology is not an element in CS Extension codes for corpus uteri carcinoma
  - Code cytology results in SSF2

NAACCR<sup>2</sup>

# CS Extension: Carcinoma & Carcinosarcoma of Corpus Uteri

- Code 000: In situ
- Codes 100-400: Confined to corpus uteri
- Codes 500-525: Invades stromal connective tissue of cervix but does not extend beyond uterus
- Codes 540-680: Extension or metastasis to serosa and/or adnexa or vagina; parametrial involvement
- Codes 715-820: Invades bladder mucosa and/or bowel mucosa

NAACCI

#### **Pop Quiz**

- Endometrial biopsy: Endometrioid adenocarcinoma.
- Total Abdominal Hysterectomy Bilateral Salpingo-oophorectomy (TAHBSO): No residual tumor.

NAACCR<sup>2</sup>

#### **Pop Quiz**

- What is the code for CS Extension?
  - 100: Invasive cancer confined to corpus uteri
  - 110: Confined to endometrium (stroma)
  - 400: Localized NOS
  - 999: Unknown
- What is the code for CS TS/Ext Eval?
  - 1: Biopsy
  - 3: Surgical resection

# CS Lymph Nodes: Carcinoma & Carcinosarcoma of Corpus Uteri

- Code involvement of regional nodes
- Record code with lymph node detail when both lymph node detail and FIGO stage are stated
- Assume nodes negative if surgery performed and lymph nodes not mentioned
- Assume nodes negative if adnexa palpated and lymph nodes not mentioned

NAACCR

# CS Mets at DX: Carcinoma & Carcinosarcoma of Corpus Uteri

- Metastasis to adnexa, parametria, serosa, vagina, pelvic wall, bladder, and rectum coded in CS Extension
- Record code with metastasis detail when both metastasis detail and FIGO stage are stated
- FIGO stage IVB is based on metastasis

NAACCR<sup>2</sup>

# SSF1: Carcinoma & Carcinosarcoma of Corpus Uteri

- FIGO stage
  - Code as documented in medical record
    - Do not try to code from T, N, M values
  - Assign code 987 for carcinoma in situ
    - CS Extension = 000
  - Assign code 999 if FIGO stage is unknown or not documented

NAACCE

# SSF2: Carcinoma & Carcinosarcoma of Corpus Uteri

- Peritoneal cytology
  - Searches for malignant cells in pelvic & peritoneal cavities
  - Code results of peritoneal or pelvic washings
  - Exam of ascites or of saline solution flooded in the pelvic & peritoneal cavities
  - Code negative, positive, or suspicious cytology
  - Assign code 998 if known that peritoneal/pelvic cytology not done
  - Assign code 999 if unknown if peritoneal/pelvic cytology performed

NAACCI

#### **Pop Quiz**

 Path report: Endometrial adenocarcinoma invading outer half of myometrium. Peritoneal washings were not evaluated but pelvic washings are positive for adenocarcinoma with features consistent with the endometrial lesion.

NAACCR<sup>2</sup>

#### **Pop Quiz**

- What is the code for SSF2 (peritoneal cytology)?
  - 000: Negative
  - 010: Positive, malignant cells positive
  - 998: Test not done
  - 999: Unknown

#### **Number of Nodes Positive & Examined**

- Involvement of regional and distant nodes is prognostic factor for gynecologic sites
- Follow coding instructions for Regional Nodes Positive and Regional Nodes Examined

NAACCR

#### **Number of Nodes Positive & Examined**

- SSF3: Number of Positive Pelvic Nodes
- SSF4: Number of Examined Pelvic Nodes
- SSF5: Number of Positive Para-aortic Nodes
- SSF6: Number of Examined Para-aortic Nodes

NAACCR<sup>2</sup>

# SSF7:Carcinoma & Carcinosarcoma of Corpus Uteri

- Percentage of Non-Endometrioid Cell Type in Mixed Histology Tumors
  - Corresponds to FIGO grade of endometrial cancer
  - Code the percentage of non-squamous or nonmorular solid growth pattern
  - Assign code 999 if grade is not based on growth pattern or if not specified

NAACCR<sup>2</sup>

#### **Pop Quiz**

- Final path diagnosis: Endometrioid adenocarcinoma, FIGO grade I: 5% or less nonsquamous solid growth"
- What is the code for SSF?
  - 001: 5% or less of a non-squamous or nonmorular solid growth pattern (Grade 1)
  - 987: Not applicable: Not an adenocarcinoma morphology
  - 999: Unknown

NAACCR<sup>2</sup>

# SSF8: Carcinoma & Carcinosarcoma of Corpus Uteri

- Omentectomy
  - Code whether or not omentectomy performed in 1<sup>st</sup> course surgery
    - Includes partial omentectomy but not biopsy
  - Code 998 if surgery not performed.

NAACCR<sup>2</sup>

# ADENOSARCOMA OF CORPUS UTERI

# CS Extension: Adenosarcoma of Corpus Uteri

- Record code with extension detail when both extension detail and FIGO stage are stated
- FIGO stage IV based on tumor extension AND metastasis
  - Code FIGO IV in CS extension if based on tumor extension
- Positive cytology is not an element in CS Extension codes for corpus uteri

NAACCR

# CS Extension: Adenosarcoma of the Corpus Uteri

- Code 000: In situ
- Codes 100-500: Limited to uterus
- Codes 550-683: Extends beyond uterus within pelvis
- Codes 688-699: Involves abdominal tissues
- Codes 705-730: Invades bladder or rectum

NAACCR<sup>\*</sup>

# CS Lymph Nodes: Adenosarcoma of Corpus Uteri

- Code involvement of regional nodes
- Record code with lymph node detail when both lymph node detail and FIGO stage are stated
- Assume nodes negative if surgery performed and lymph nodes not mentioned
- Assume nodes negative if adnexa palpated and lymph nodes not mentioned

NAACCR<sup>2</sup>

# CS Mets at DX: Adenosarcoma of Corpus Uteri

- Record code with metastasis detail when both metastasis detail and FIGO stage are stated
- FIGO stage IV based on tumor extension AND metastasis
  - Code FIGO stage IV in CS Mets at DX if based on metastasis or if no statement that FIGO stage IV is based on extension

NAACCR<sup>2</sup>

#### SSF1: Adenosarcoma of Corpus Uteri

- FIGO stage
  - Code as documented in medical record
    - Do not try to code from T, N, M values
  - Assign code 987 for carcinoma in situ
    - CS Extension = 000
  - Assign code 999 if FIGO stage is unknown or not documented

NAACCR<sup>\*</sup>

#### SSF2: Adenosarcoma of Corpus Uteri

- Peritoneal cytology
  - Searches for malignant cells in pelvic & peritoneal cavities
  - Code results of peritoneal or pelvic washings
  - Exam of ascites or of saline solution flooded in the pelvic & peritoneal cavities
  - Code negative, positive, or suspicious cytology
  - Assign code 998 if known that peritoneal/pelvic cytology not done
  - Assign code 999 if unknown if peritoneal/pelvic cytology performed

#### **Number of Nodes Positive & Examined**

- SSF3: Number of Positive Pelvic Nodes
- SSF4: Number of Examined Pelvic Nodes
- SSF5: Number of Positive Para-aortic Nodes
- SSF6: Number of Examined Para-aortic Nodes

NAACCR

#### SSF7: Adenosarcoma of Corpus Uteri

- Percentage of Non-Endometrioid Cell Type in Mixed Histology Tumors
  - Assign code 987 (Not applicable: Not an adenocarcinoma morphology)

NAACCR<sup>2</sup>

#### SSF8: Adenosarcoma of Corpus Uteri

- Omentectomy
  - Code whether or not omentectomy performed in 1<sup>st</sup> course surgery
    - Includes partial omentectomy but not biopsy
  - Code 998 if surgery not performed.

SARCOMA (LEIOMYOSARCOMA & ENDOMETRIAL STROMAL SARCOMA)
OF CORPUS UTERI

### **CS Extension: Sarcoma of Corpus Uteri**

- Record code with extension detail when both extension detail and FIGO stage are stated
- FIGO stage IV based on tumor extension AND metastasis
  - Code FIGO IV in CS extension if based on tumor extension
- Positive cytology is not an element in CS Extension codes for corpus uteri

NAACCR<sup>2</sup>

### CS Extension: Sarcoma of the Corpus Uteri

- Code 000: In situ
- Codes 100-540: Limited to uterus
- Codes 550-683: Extends beyond uterus within pelvis
- Codes 688-699: Infiltrates abdominal tissues
- Codes 705-730: Invades bladder or rectum

NAACCI

### **CS Lymph Nodes: Sarcoma of Corpus Uteri**

- Code involvement of regional nodes
- Record code with lymph node detail when both lymph node detail and FIGO stage are stated
- Assume nodes negative if surgery performed and lymph nodes not mentioned
- Assume nodes negative if adnexa palpated and lymph nodes not mentioned

NAACCR

### CS Mets at DX: Sarcoma of Corpus Uteri

- Record code with metastasis detail when both metastasis detail and FIGO stage are stated
- FIGO stage IV based on tumor extension AND metastasis
  - Code FIGO stage IV in CS Mets at DX if based on metastasis

NAACCR<sup>2</sup>

#### SSF1: Sarcoma of Corpus Uteri

- FIGO stage
  - Code as documented in medical record
    - Do not try to code from T, N, M values
  - Assign code 987 for carcinoma in situ
    - CS Extension = 000
  - Assign code 999 if FIGO stage is unknown or not documented

#### SSF2: Sarcoma of Corpus Uteri

- Peritoneal cytology
  - Searches for malignant cells in pelvic & peritoneal cavities
  - Code results of peritoneal or pelvic washings
  - Exam of ascites or of saline solution flooded in the pelvic & peritoneal cavities
  - Code negative, positive, or suspicious cytology
  - Assign code 998 if known that peritoneal/pelvic cytology not done
  - Assign code 999 if unknown if peritoneal/pelvic cytology performed

NAACCI

#### **Number of Nodes Positive & Examined**

- SSF3: Number of Positive Pelvic Nodes
- SSF4: Number of Examined Pelvic Nodes
- SSF5: Number of Positive Para-aortic Nodes
- SSF6: Number of Examined Para-aortic Nodes

NAACCR<sup>2</sup>


#### SSF7: Sarcoma of Corpus Uteri

- Percentage of Non-Endometrioid Cell Type in Mixed Histology Tumors
  - Assign code 987 (Not applicable: Not an adenocarcinoma morphology)

NAACCE

# SSF8: Sarcoma of Corpus Uteri Omentectomy Code whether or not omentectomy performed in 1st course surgery Includes partial omentectomy but not biopsy Code 998 if surgery not performed.







<ul> <li>Cervix</li> <li>PAP Smear</li> <li>Colposcopy</li> <li>Biopsy</li> <li>Cone biopsy</li> </ul>	<ul><li>Imaging</li><li>MRI</li><li>CT</li><li>PET-CT</li></ul>	
		NAACCR

Diagnostic Procedures	
Endometrium     Endometrial biopsy     Fractional dilation and curettage (D&C)     Hysteroscopy     Imaging     CT     MRI	
	NAACCR

# Treatment-Cervix • Early-Stage - IA1-IIA2 • Advanced Disease - IIB-IVA

#### **Treatment-Cervix**

- Surgery
  - Primary treatment for lower stage disease and small lesions
    - Clinically visible tumors less than 4cm
  - Radical hysterectomy or radical trachelectomy
  - Pelvic lymph node dissection

NAACCR<sup>2</sup>

#### Question

- Patient with cervix primary with parametrial extension underwent BSO only. (Uterus was left in place for planned brachytherapy).
  - Would it be correct to code the BSO as Surgery
     Other Reg Site and code Surgery Primary Site 00?
  - If not, how should this surgery be coded?

#### **Answer**

 Assuming cervix was not removed, your coding scenario is correct - Surgical Procedure of Primary Site would be 00, and BSO as Surgical Procedure Other REGIONAL Sites.

NAACCR

#### **Treatment-Cervix**


- Chemo-radiation
  - Usually platinum based (Cisplatin) chemotherapy
  - External Beam Radiation
    - IMRT or 3D Conformal
  - Brachytherapy


NAACCR<sup>2</sup>


#### **External Beam Radiation Therapy (EBRT)**

 The volume of EBRT should cover the gross disease, parametria, uterosacral ligaments, sufficient vaginal margin, presacral nodes, other nodal volumes at risk









#### **Total Hysterectomy**

- Commonly referred to as simple hysterectomy.
- This hysterectomy removes the uterine corpus and cervix, but does not require mobilization of the ureter or removal of the parametria.




#### **Modified Radical Hysterectomy**

- Removes corpus, cervix and 1-2 cm of the upper vagina, with preservation of the vascular supply to the ureter.
- Removes the central portion of the parametrial tissues and pelvic and para-aortic lymph nodes.



#### **Extended Hysterectomy**

- Removes corpus, cervix and 1-2 cm of the upper vagina, with preservation of the vascular supply to the ureter and bladder.
- Extensive removal of the parametrial tissue and pelvic and paraaortic lymph nodes.



#### **Radical hysterectomy**

- Removes corpus, cervix, and 2- to 3-cm portion of the upper vagina.
   Removes as much parametrial tissue as possible.
- Removes the pelvic and para-aortic lymph nodes.



#### **Peritoneal Lavage**

- Malignant cells have been identified in ~10% of presumed localized endometrial primaries
  - A procedure in which a salt-water solution is used to wash the peritoneal cavity and then is removed to check for cancer cells

NAACCR<sup>2</sup>

#### **Debulking**

 All visible metastasis are removed from the abdominal and pelvic cavity

NAACCD

#### Question

- How would omentectomy be coded for the following scenario?
  - TAH-BSO and omentectomy is performed for stage IA endometrial carcinoma. No mention that the surgeon suspected omental involvement, and the pathology exam confirmed no tumor in the omentum.
- Would the omentectomy be considered a staging procedure, or would it be coded as surgery of other regional/distant site?

NAACCR

#### **Answer**


- The omentectomy is elective in this range of codes, so the code is based on the actual extent of the resection en-bloc, and whether the parametria, ureter, vessels, and ligaments were preserved or sacrificed.
  - Please review the description of few types of hysterectomy that are different by amount of additional tissue removed.
    - CAnswer Forum
      - http://cancerbulletin.facs.org/forums/showthread.php?5294quot-Staging-Omentectomy-quot-for-uterineprimaries&highlight=omentectomy

NAACCR<sup>2</sup>

#### **Systemic Therapy**

- Chemotherapy
  - Cisplatin/doxorubicin plus or minus paclitaxel
- Hormone therapy
  - Sometimes used for metastatic or recurrent endometrioid primaries and select uterine sarcomas
    - Progestational agents
    - Tamoxifin
    - Aromatase inhibitors





Coming up!
• 12/6/12
Collecting Cancer Data: Pharynx • 1/10/13
Bone and Soft Tissue
Certificate phrase:
- http://www.surveygizmo.com/s3/1071411/Uterus
NAACCR



